This is a preview of subscription content, log in via an institution to check access.
Notes
76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology Health Professionals
American College of Rheumatology 20%, 50% and 70% response criteria
References
Carlson JJ, et al. Cost-Effectiveness of Tocilizumab Monotherapy Vs. Adalimumab Monotherapy in the Treatment of Severe Active Rheumatoid Arthritis. 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals : abstr. 2463, 9 Nov 2012. Available from: URL: http://www.rheumatology.org/apps/MyAnnualMeeting/ExploreMeeting/AbstractDetail?abstractId=29113
Navarro Sarabia F, et al. Pharmacoeconomic Evaluation of Tocilizumab Monotherapy Vs. Adalimumab Monotherapy in Reducing Disease Activity in Patients with Rheumatoid Arthritis. 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals : abstr. 2173, 9 Nov 2012. Available from: URL: http://www.rheumatology.org/apps/MyAnnualMeeting/ExploreMeeting/AbstractDetail?abstractId=31383
Rights and permissions
About this article
Cite this article
Tocilizumab dominates adalimumab for severe RA. PharmacoEconomics & Outcomes News 669, 7 (2013). https://doi.org/10.1007/s40274-013-0056-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0056-8